The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms

Completed · Phase 1

Conditions studied: Alzheimer's Disease (AD)

In brief

The investigators' goal is to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam, can predict whether or not an individual is at risk for developing Alzheimer's disease.

Key facts

Study ID

NCT01780519

Run by

Mayo Clinic

People needed

57

Starts

2013-01-01

Expected to finish

2016-09-01

Last updated by the study team

2016-11-10

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Mini-Mental State Examination (MMSE) score of 28-30
• Hamilton Depression Rating Scale score of less than 10
• participants in longitudinal study of aging and have a TOMM40 genotype of S/S, VL/VL, S/VL, L/S or L/VL.

You may not qualify if…

• Alzheimer's Disease or Mild Cognitive Impairment
• any significant medical, psychiatric, and neurological illnesses, e.g., impaired liver or kidney function, prior stroke, traumatic brain injury, memory impairment, cognitive impairment, parkinsonism, a lifetime history of schizophrenia, bipolar disorder, a psychoactive substance use disorder, or current major depression.
• known allergy to benzodiazepines
• current use (within the previous four weeks) of benzodiazepines or other medications known to interact with lorazepam, current use of sedating antihistamines, or current use of stimulant medications

Where it is running

• Mayo Clinic — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.